The U.S. Food and Drug Administration (FDA) granted orphan drug status to an investigational therapy being developed by MediciNova, Inc. to treat Krabbe disease. The company expects MN-166 (ibudilast) to become a treatment option for the rare genetic degenerative condition that affects children at early age, causing the weakening of…
News
The Muscular Dystrophy Association is offering an exclusive opportunity to those who want to participate in the sold out 2015 Bank of America Chicago and Marine Corps Marathons. The MDA is offering a secure, guaranteed entry by signing up through MDA Team Momentum, the organization’s nationwide endurance program. Space, however,…
Merozyne Therapeutics AB recently initiated a project with the goal of developing a pharmaceutical treatment to address laminin alpha2 chain-deficient congenital muscular dystrophy (MDC1A) through supporting the research that Madeleine Durbeej-Hjalt and Virginie Carmignac conducted at Lund University. Merozyne Therapeutics AB has been established very recently by several entrepreneurial life science firms based at the Medicon…
The 5th Annual Getzlaf Golf Shootout to benefit CureDuchenne will take place on September 12th at Sutra Lounge in Costa Mesa, California and September 13th at the Monarch Beach Golf Links in Dana Point, California. The event will be hosted by the captain of the Anaheim Ducks, …
In a new study entitled “Under-recognition of Low Blood Pressure Readings in Patients with Duchenne Muscular Dystrophy,” researchers determined for the first time how blood pressure is affected in patients with duchenne muscular dystrophy. They report a significant portion of DMD patients exhibit low blood pressure, and highlight the need for clinicians…
The FSH Society, a Massachusetts-based charity supporting research into facioscapulohumeral muscular dystrophy (FSHD), has announced that it recently completed the 2nd edition of the FSHD Trial Preparedness Workshop, which was held between May 29 and 30, 2015 at the University of Rochester Medical Center in Rochester, New York. The workshop included over 50 stakeholders from around…
A new study published in the journal Human Molecular Genetics revealed a new therapeutic approach that could potentially alter the progression of muscle damage and dysfunction in patients with myotonic dystrophy. The study is entitled “TWEAK/Fn14, a pathway and novel therapeutic target in myotonic…
In a recent study published in Oncotarget, researchers found an inverse correlation between the level of muscle fibrosis, utrophin and the number of revertant myofibers in Duchenne Muscular Dystrophy (DMD). Results from this study reveal common links between the fibrotic and utrophin-synthesis pathways and offer new insights into…
A new collaborative group involving academic and industry researchers and patient advocacy groups conducted a large-scale study to find serum biomarkers for Duchenne muscular dystrophy (DMD). The study was recently published in the journal Proceedings of the National Academy of Sciences (PNAS) and is entitled “…
The Muscular Dystrophy Association (MDA) has begun another season of its well known summer camp, marking its 60th year in operation. The MDA summer camp aims to support families by hosting thousands of children struggling against muscular dystrophy and similar conditions that seriously limit their mobility and muscular strength. The summer camp assists kids in helping them…
Recent Posts
- I have 5 essential tools for managing cold and flu season with Duchenne MD
- FDA fast tracks Dyscorban for treating heart problems in Duchenne
- My emotions blurred as I watched my play from ‘The Other Side’
- MDA-led project to map how human muscles repair themselves
- My willingness to educate others about MD benefits all of us